Home » Catalyst Starts Enrolling Patients with Methamphetamine Addiction
Catalyst Starts Enrolling Patients with Methamphetamine Addiction
Patients who are addicted to methamphetamine are enrolling in Catalyst Pharmaceuticals’ Phase II clinical trial using CPP-109.
CPP-109 is an orally administered, small molecule drug that inhibits psychostimulant-induced dopamine release. It is the company’s version of vigabatrin, an anticonvulsant that has shown promise in treating substance dependency.
The randomized, double-blind, placebo-controlled, multicenter trial will evaluate the safety and efficacy of the drug in 180 patients at 15 addiction treatment centers in the U.S. Patients will be treated for a period of 12 weeks with an additional 12 weeks of follow-up, Catalyst said.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May